Skip to content
Main Navigation
About us
Company profile
Our values
Our strategy
Board of Directors
Senior management
Our history
Research and development
Technology platform
Therapeutic areas
Pipeline
Scientific papers and presentations
Partnering
Our approach
Our partnerships
Investors
Financial reports and presentations
Share information
Analyst coverage
Major shareholders
Financial calendar
Corporate governance
Corporate governance statements
Dividend policy
Annual general meeting
Articles of association
Safe harbour statement
Whistleblower policy
Risk management
Investor relations policy
ESG
Email alerts
Newsroom
Press Releases
Image library
Glossary
Email alerts
Careers
Search
Research and development
Scientific papers and presentations
Sharing our discoveries and developments in our tireless pursuit of breakthrough therapies
Newest first
Oldest first
Posters & Papers
Presentations
Search
Reset
16/10/2019
CONSIDERATIONS AND EXPERIENCES FROM TAKING A FULLY PERSONALIZED TARGETED CANCER NEOANTIGEN DNA VACCINE INTO THE CLINIC | London, October 2019
10/09/2019
KEY LEARNINGS FROM BRINGING A FULLY PERSONALIZED CANCER NEOANTIGEN VACCINE INTO THE CLINIC | Boston, September 2019
09/09/2019
LUNCH PRESENTATION, ARCTIC SECURITIES – OSLO 04 SEPTEMBER 2019
26/06/2019
VACCIBODY ANNOUNCES STRONG NEOANTIGEN-SPECIFIC T CELL RESPONSES INDUCED IN CANCER PATIENTS WITH LOW MUTATIONAL BURDEN AFTER VB10.NEO VACCINATION Oslo, June 26, 2019
20/05/2019
BRINGING INDIVIDUALISED NEOANTIGEN-BASED CANCER VACCINES INTO THE CLINIC; CHALLENGES, LEARNINGS & VICTORIES | Amsterdam, April 2019
Pages:
1
2
3
4
5
6
7
8
9
10
Load more
Sorry, nothing found in this query
Privacy statement
Cookie policy
Disclaimer
